Gentium SpA PT Raised to $35.00 (GENT)
Wedbush boosted their target price on shares of Gentium SpA (NASDAQ:GENT) to $35.00 in a research note issued on Monday, Stock Ratings Network reports. Wedbush’s price target would suggest a potential upside of 39.39% from the stock’s previous close.
A number of other analysts have also recently weighed in on GENT. Analysts at Zacks downgraded shares of Gentium SpA (NASDAQ:GENT) from an “outperform” rating to a “neutral” rating in a research note to investors on Thursday, August 29th. They now have a $23.00 price target on the stock. Separately, analysts at Brean Capital raised their price target on shares of Gentium SpA (NASDAQ:GENT) from $21.00 to $24.00 in a research note to investors on Wednesday, August 14th. They now have a “buy” rating on the stock.
Shares of Gentium SpA (NASDAQ:GENT) opened at 25.11 on Monday. Gentium SpA has a one year low of $6.96 and a one year high of $25.98. The stock has a 50-day moving average of $20.29 and a 200-day moving average of $11.69. The company has a market cap of $381.0 million and a price-to-earnings ratio of 85.99.
Gentium SpA (NASDAQ:GENT) last posted its quarterly earnings results on Tuesday, August 13th. The company reported $0.16 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.02 by $0.14. On average, analysts predict that Gentium SpA will post $0.51 earnings per share for the current fiscal year.
Gentium S.p.A. is a biopharmaceutical company focused on the development and manufacture of defibrotide, a drug based on single-stranded deoxyribonucleic acid (NASDAQ:GENT) derived from pig intestines.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.